Role of Psychedelics in Treatment-Resistant Depression

Shubham Kamal; Manish Kumar Jha; Rajiv Radhakrishnan

doi:10.1016/j.psc.2023.02.004

Role of Psychedelics in Treatment-Resistant Depression

Shubham Kamal, Manish Kumar Jha, Rajiv Radhakrishnan

Research output: Contribution to journal › Review article › peer-review

Original language	English (US)
Pages (from-to)	291-305
Number of pages	15
Journal	Psychiatric Clinics of North America
Volume	46
Issue number	2
DOIs	https://doi.org/10.1016/j.psc.2023.02.004
State	Published - Jun 2023

Keywords

Ayahuasca
DMT
LSD
MDMA
Pharmacology
Psilocybin
Psychedelic
Treatment-resistant depression

ASJC Scopus subject areas

Psychiatry and Mental health

Access to Document

10.1016/j.psc.2023.02.004

Cite this

@article{3b5b54b90c1142049a65d844db4807c0,

title = "Role of Psychedelics in Treatment-Resistant Depression",

keywords = "Ayahuasca, DMT, LSD, MDMA, Pharmacology, Psilocybin, Psychedelic, Treatment-resistant depression",

author = "Shubham Kamal and Jha, {Manish Kumar} and Rajiv Radhakrishnan",

note = "Funding Information: Dr S. Kamal has nothing to disclose. Dr R. Radhakrishnan has received research funding/support from Wallace Research Foundation, United States , Neurocrine Biosciences and Jazz Pharmaceuticals . Dr M. Jha has received contract research grants from ACADIA Pharmaceuticals, United States , Neurocrine Bioscience , Navitor/Supernus , and Janssen Research & Development, United States , an educational grant to serve as Section Editor of the Psychiatry & Behavioral Health Learning Network, consultant fees from Eleusis Therapeutics US, Inc, Janssen Global Services, Janssen Scientific Affairs, Worldwide Clinical Trials/Eliem and Inversargo, and Guidepoint Global, and honoraria from North American Center for Continuing Medical Education, Medscape/WebMD, Clinical Care Options, and Global Medical Education. Funding Information: Dr S. Kamal has nothing to disclose. Dr R. Radhakrishnan has received research funding/support from Wallace Research Foundation, United States, Neurocrine Biosciences and Jazz Pharmaceuticals. Dr M. Jha has received contract research grants from ACADIA Pharmaceuticals, United States, Neurocrine Bioscience, Navitor/Supernus, and Janssen Research & Development, United States, an educational grant to serve as Section Editor of the Psychiatry & Behavioral Health Learning Network, consultant fees from Eleusis Therapeutics US, Inc, Janssen Global Services, Janssen Scientific Affairs, Worldwide Clinical Trials/Eliem and Inversargo, and Guidepoint Global, and honoraria from North American Center for Continuing Medical Education, Medscape/WebMD, Clinical Care Options, and Global Medical Education.",

year = "2023",

month = jun,

doi = "10.1016/j.psc.2023.02.004",

language = "English (US)",

volume = "46",

pages = "291--305",

journal = "Psychiatric Clinics of North America",

issn = "0193-953X",

publisher = "W.B. Saunders Ltd",

number = "2",

}

TY - JOUR

T1 - Role of Psychedelics in Treatment-Resistant Depression

AU - Kamal, Shubham

AU - Jha, Manish Kumar

AU - Radhakrishnan, Rajiv

N1 - Funding Information: Dr S. Kamal has nothing to disclose. Dr R. Radhakrishnan has received research funding/support from Wallace Research Foundation, United States , Neurocrine Biosciences and Jazz Pharmaceuticals . Dr M. Jha has received contract research grants from ACADIA Pharmaceuticals, United States , Neurocrine Bioscience , Navitor/Supernus , and Janssen Research & Development, United States , an educational grant to serve as Section Editor of the Psychiatry & Behavioral Health Learning Network, consultant fees from Eleusis Therapeutics US, Inc, Janssen Global Services, Janssen Scientific Affairs, Worldwide Clinical Trials/Eliem and Inversargo, and Guidepoint Global, and honoraria from North American Center for Continuing Medical Education, Medscape/WebMD, Clinical Care Options, and Global Medical Education. Funding Information: Dr S. Kamal has nothing to disclose. Dr R. Radhakrishnan has received research funding/support from Wallace Research Foundation, United States, Neurocrine Biosciences and Jazz Pharmaceuticals. Dr M. Jha has received contract research grants from ACADIA Pharmaceuticals, United States, Neurocrine Bioscience, Navitor/Supernus, and Janssen Research & Development, United States, an educational grant to serve as Section Editor of the Psychiatry & Behavioral Health Learning Network, consultant fees from Eleusis Therapeutics US, Inc, Janssen Global Services, Janssen Scientific Affairs, Worldwide Clinical Trials/Eliem and Inversargo, and Guidepoint Global, and honoraria from North American Center for Continuing Medical Education, Medscape/WebMD, Clinical Care Options, and Global Medical Education.

PY - 2023/6

Y1 - 2023/6

KW - Ayahuasca

KW - DMT

KW - LSD

KW - MDMA

KW - Pharmacology

KW - Psilocybin

KW - Psychedelic

KW - Treatment-resistant depression

UR - http://www.scopus.com/inward/record.url?scp=85151450960&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85151450960&partnerID=8YFLogxK

U2 - 10.1016/j.psc.2023.02.004

DO - 10.1016/j.psc.2023.02.004

M3 - Review article

C2 - 37149346

AN - SCOPUS:85151450960

SN - 0193-953X

VL - 46

SP - 291

EP - 305

JO - Psychiatric Clinics of North America

JF - Psychiatric Clinics of North America

IS - 2

ER -

Role of Psychedelics in Treatment-Resistant Depression

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this